WO1997000698A1 - Inhibition of hepatitis b replication - Google Patents
Inhibition of hepatitis b replication Download PDFInfo
- Publication number
- WO1997000698A1 WO1997000698A1 PCT/US1996/010602 US9610602W WO9700698A1 WO 1997000698 A1 WO1997000698 A1 WO 1997000698A1 US 9610602 W US9610602 W US 9610602W WO 9700698 A1 WO9700698 A1 WO 9700698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leu
- amino acid
- ser
- pro
- hepadnavirus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- Hepatitis B virus is a member of the hepadnavirus family, a group of enveloped DNA viruses that cause acute and chronic hepatitis.
- Major clinical consequences of HBV infection include acute liver failure, liver cirrhosis, and primary hepatocellular carcinoma (HCC) .
- HCC primary hepatocellular carcinoma
- Hepadnaviruses are composed of a viral envelope, a nucleocapsid which contains a relaxed circular 3.2 kb DNA genome, and a virally encoded reverse transcriptase.
- virion DNA is delivered to the nucleus where it is converted into a covalently closed circular DNA (cccDNA) , which is in turn transcribed into several subgenomic and pregenomic mRNAs.
- the pregenomic RNA is then encapsidated into the viral nucleocapsid, together with the reverse transcriptase enzyme necessary to generate the viral DNA genome (Enders et al., J. Virol . , 67, 35-41, 1987).
- the mammalian hepadnavirus 21 kd core protein is a 183-187 (depending on the viral strain) amino acid monomer, 180 of which self assemble into an icosahedral structure within the cytoplasm of infected cells.
- the core protein has two functional domains.
- the aminoterminus (amino acids 1 to 139-44) is essential for core assembly.
- a carboxyterminal arginine-rich region (amino acids 139-183, or 144-187, depending upon the viral strain) binds nucleic acids that are required for positive strand DNA synthesis, and stabilizes core particles for complete assembly of the complex into an enveloped viral particle (Birnbaum et al. J. Virol . , 64. 3319-3330, 1990; Yu et al. - J. Virol . , 65, 2511-2517, 1990; Nassal, M. , supra) .
- the invention is based on Applicants' discovery that altering the carboxyterminus of the hepadnavirus core protein creates a mutant polypeptide that reduces replication of a wild type hepadnavirus, by a dominant negative mechanism.
- the inhibitory effect is achieved by deletion of a few carboxyterminal amino acids from the core protein, and/or by joining the core protein to a hepadnavirus surface protein, thereby creating a core- surface fusion polypeptide.
- the invention features a method of inhibiting the replication of a naturally-occurring, infectious hepadnavirus.
- the method involves introducing into the proximity of the hepadnavirus a hepadnavirus mutant polypeptide, or a nucleic acid that encodes such a hepadnavirus mutant polypeptide.
- the polypeptide includes a first amino acid sequence that is substantially identical to a region of a wild type hepadnavirus core protein, but lacks a second amino acid sequence of the wild type hepadnavirus core protein, wherein the second sequence includes the carboxyterminal three amino acids of the wild-type hepadnavirus core protein and does not exceed 100 amino acids in length.
- the mutant polypeptide is introduced into the infected cell, or is expressed from the nucleic acid, in the proximity of the naturally-occurring hepadnavirus, so as to be available to inhibit replication of the hepadnavirus.
- the carboxyterminal amino acid of the first amino acid sequence can be selected from the group consisting of any of the amino acids between position 81 and position 180 of the sequence shown in Fig. 15 (SEQ ID NO: 12) , inclusive; preferably the carboxyterminal amino acid is chosen from the group consisting of the amino acids between position 171 and position 180 of the sequence shown in Fig. 15 (SEQ ID NO: 12) , inclusive.
- a construct exemplified herein ends with a carboxyterminal residue at position 171, so that the mutant core protein includes amino acids 1-171 (Fig. 15 (SEQ ID NO: 12)).
- the carboxyterminal amino acid is amino acid 178, so that the mutant core protein includes amino acids 1-178 (Fig. 15 (SEQ ID NO: 12)), corresponding to a five amino acid deletion from the carboxyterminus (see, e.g., the analogous duck hepatitis B virus (DHBV) construct pBK, which is described below) .
- the first amino acid sequence is at least 70 amino acids in length, e.g., 72, 74, 76, 78, or 80 amino acids in length.
- the aminoterminal amino acid of the first amino acid sequence can be the first amino acid of the corresponding wild type hepadnavirus sequence.
- nonessential aminoterminal amino acids can be eliminated from the mutant polypeptide, provided that the resulting mutant polypeptide does not lose substantial inhibitory activity as a result, when tested according to the methods described below.
- the mutant polypeptide further includes a third amino acid sequence.
- the third amino acid sequence is substantially identical to a portion of a wild type hepadnavirus surface protein.
- the aminoterminal amino acid of the third amino acid sequence may be joined by a peptide bond to the carboxyterminal amino acid of the first amino acid sequence so as to create a fusion protein.
- the third amino acid sequence can be the entire surface protein, or can be a portion thereof, e.g., a portion of at least 4, 8, 20, 30, or 43 amino acids in length.
- the aminoterminal amino acid of the third amino acid sequence can be selected from the group consisting of the amino acids between position 1 and position 112 of the sequence shown in Fig. 16 (SEQ ID NO: 14) , inclusive, preferably the amino acids between position 1 and position 8, inclusive.
- Preferred aminoterminal amino acids of the third amino acid sequence exemplified herein include, but are not limited to, position 5 or position 8 of Fig. 16 (SEQ ID NO: 14).
- the carboxyterminal amino acid of the third amino acid sequence can be selected from a group that includes any of the amino acids between position 51 and position 224 of Fig. 16 (SEQ ID NO: 14), inclusive; e.g., any of the amino acids between position 112 and position 224 of Fig. 16 (SEQ ID NO: 14), inclusive; e.g., the carboxyterminal amino acid may be position 51, position 112, or position 224 of Fig. 16 (SEQ ID NO: 14).
- the portion of the surface protein included on the mutant polypeptide preferably includes surface protein residues 1-112, 8-112, or 8-51, all inclusive (Fig. 16; SEQ ID NO: 14).
- the use of a core protein for inhibiting viral replication is a species-specific event, so that mutant core proteins inhibit nucleocapsid assembly in the same type of hepadnavirus from which they were derived.
- the first amino acid sequence is substantially identical to a region of a wild type hepadnavirus core protein that is derived from the same type of hepadnavirus (e.g., HBV versus DHBV) as the naturally-occurring hepadnavirus targeted for inhibition.
- the third amino acid sequence may be substantially identical to a portion of a wild type hepadnavirus surface protein of any hepadnavirus species, since the surface proteins do not demonstrate species specificity.
- the mutant polypeptide when the method of the invention is used to treat an HBV infection, should include sequences specifically derived from the HBV core protein Fig. 15 (SEQ ID NO: 12) , but can include sequences derived from any species of surface protein (e.g., the sequence of Fig. 16 (SEQ ID NO: 14)).
- the invention features a nucleic acid that encodes a mutant hepatitis B virus (HBV) polypeptide, the polypeptide including a first amino acid sequence that is substantially identical to a region of a wild type HBV core protein, and lacking a second amino acid sequence of the wild type HBV core protein.
- the second sequence includes the carboxyterminal three amino acids of the wild type HBV core protein and does not exceed nine amino acids in length.
- the carboxyterminal amino acid of the first amino acid sequence can be at position 174, position 175, position 176, position 177, position 178, position 179, or position 180, all of Fig. 15 (SEQ ID NO: 12).
- the invention features a nucleic acid that encodes a mutant hepadnavirus polypeptide.
- the polypeptide includes a first amino acid sequence that is substantially identical to a region of a wild type hepadnavirus core protein; lacks a second amino acid sequence of the wild type hepadnavirus core protein which includes at least the carboxyterminal three amino acids of the wild type hepadnavirus core protein; and includes a third amino acid sequence that is substantially identical to a portion, or all, of a wild type hepadnavirus surface protein.
- the aminoterminal amino acid of the third amino acid sequence may be joined by a peptide bond to the carboxyterminal amino acid of the first amino acid sequence so as to create a fusion protein.
- the carboxyterminal amino acid of the first amino acid sequence can be any of the amino acids between position 71 and position 180 of Fig. 15 (SEQ ID NO: 12) , inclusive.
- the second amino acid sequence does not exceed 100 amino acids in length.
- the invention also features polypeptides encoded by any of the various nucleic acids of the invention.
- a polypeptide of the invention can be included in a therapeutic composition as an active ingredient, along with a pharmaceutically acceptable carrier, or it can be expressed from the nucleic acid within the infected cell.
- the invention also features vectors into which are inserted any of the various nucleic acids of the invention.
- the vector can include any sequence known to those of skill in the art necessary or desirable for replicating the vector in a eukaryotic cell or for expressing a polypeptide of the invention from the coding sequences thereon.
- the nucleic acid sequence can be operatively linked to appropriate transcription and/or translation control sequences that function in a eukaryotic cell.
- the vector can be any vector suitable for maintaining or making multiple copies of a nucleic acid of the invention, or can be one that is suitable for administering a nucleic acid of the invention to a cell or to a mammal infected with a hepadnavirus, e.g., to a human patient infected with HBV or to cells removed from the patient for ex vivo gene therapy.
- vectors useful in the method of inhibiting a hepadnavirus include, but are not limited to, adenovirus vectors, adeno-associated vectors, and retroviral vectors. Any of the various vectors of the invention can be included in a therapeutic composition along with a pharmaceutically acceptable carrier.
- the invention includes a method of evaluating a candidate polypeptide for its ability to inhibit the replication of a naturally-occurring hepadnavirus.
- the method involves introducing a mutant hepadnavirus polypeptide as described above into a medium in the presence of the hepadnavirus and determining whether hepadnavirus replication is inhibited in the presence of the polypeptide, compared to in its absence, such inhibition being an indication that the polypeptide is an inhibitor of hepadnavirus replication.
- medium is meant an environment that is capable of supporting viral replication by virtue of its chemical composition.
- the medium can be within an organism, e.g., an animal model, or can be within an organ removed from an animal.
- the medium can also be an intracellular medium, e.g., in a cell culture assay, or a cell-free extract, e.g., a cell free replication system.
- a cell culture assay e.g., Huh-6, Huh-7, HepG2, HepG2 2215, LMH, DC, and HCC cells.
- the polypeptide can be introduced to the medium by introducing into the medium a nucleic acid encoding the polypeptide, with subsequent expression of the polypeptide therein.
- Another method of inhibiting the replication of a naturally-occurring hepadnavirus involves introducing into the proximity of the hepadnavirus a hepadnavirus mutant polypeptide, or a nucleic acid that encodes a hepadnavirus mutant polypeptide.
- the polypeptide includes a first amino acid sequence that is substantially identical to a region of, or all of, a wild type hepadnavirus core protein, and a second amino acid sequence which is substantially identical to a portion of, or all of, a wild type hepadnavirus surface protein.
- the aminoterminal amino acid of the second amino acid sequence may be joined by a peptide bond to the carboxyterminal amino acid of the first amino acid sequence so as to create a fusion protein.
- the second amino acid sequence can be the entire surface protein, or can be a portion thereof.
- the mutant polypeptide is expressed from the nucleic acid in the proximity of the naturally-occurring hepadnavirus, so as to be available to inhibit replication of the hepadnavirus.
- the invention includes a hepadnavirus mutant polypeptide, or a nucleic acid that encodes a hepadnavirus mutant polypeptide.
- the polypeptide includes a first amino acid sequence that is substantially identical to a region, or all, of a wild type hepadnavirus core protein, and a second amino acid sequence which is substantially identical to a portion, or all, of a wild type hepadnavirus surface protein.
- the aminoterminal amino acid of the second amino acid sequence may be joined by a peptide bond to the carboxyterminal amino acid of the first amino acid sequence so as to create a fusion protein.
- the second amino acid sequence can be the entire surface protein, or can be a portion thereof.
- hepadnavirus refers to a member of the hepadnavirus family of viruses, including, but not limited to, hepatitis B virus and hepatitis delta virus (Wang et al., Nature, 323:508-13, 1986). Although treatment of HBV is an important feature of the method of invention due to the incidence of HBV-related human disease, the methods described herein also apply to other species of hepadnaviruses.
- hepadnaviruses within the scope of the invention include, but are not limited to, hepadnaviruses infecting various human organs, including liver cells, exocrine and endocrine cells, tubular epithelium of the kidney, spleen cells, leukocytes, lymphocytes, e.g., splenic, peripheral blood, B or T lymphocytes, and cells of the lymph nodes and pancreas (see, e.g., Mason et al., Hepatology, 9:635-645, 1989) .
- the invention also applies to hepadnaviruses infecting non-human mammalian species, such as domesticated livestock or household pets.
- the invention includes a method of evaluating a candidate mutant polypeptide for its ability to inhibit hepadnavirus replication.
- a variety of hepadnavirus species are useful models. Examples include, but are not limited to, woodchuck hepatitis virus (WHV; Summers et al. Proc. Natl. Acad Sci. USA, 75:4533-37, 1978), duck hepatitis B virus (DHBV; Mason et al. J. Virol. 36:829- 36, 1978), and squirrel hepatitis virus (e.g., Marion et al. Proc. Natl. Acad Sci. USA, 77:2941-45, 1980).
- WBV woodchuck hepatitis virus
- DHBV duck hepatitis B virus
- squirrel hepatitis virus e.g., Marion et al. Proc. Natl. Acad Sci. USA, 77:2941-45, 1980.
- a "naturally-occurring" hepadnavirus refers to a form or sequence of the virus as it exists in an animal, e.g., a natural isolate derived from an infected animal.
- a "naturally-occurring" hepadnavirus is intended to be synonymous with the sequence known to those skilled in the art as the "wild type" sequence, e.g., the wild type HBV core and surface protein sequences shown in Figs. 15 and 16 (SEQ ID NOs: 11-14) .
- amino acid sequence of a core or surface protein of a hepadnavirus that is derived from a natural isolate differs from the conventionally accepted "wild type" sequence, it is understood that the sequence of the natural isolate may be the proper comparison sequence for designing mutant polypeptides of the invention.
- Sequence identity refers to the subunit sequence similarity between two nucleic acid or polypeptide molecules. When a given position in both of the two molecules is occupied by the same nucleotide or amino acid residue, e.g., if a given position in each of two polypeptides is occupied by serine, then they are identical at that position.
- the identity between two sequences is a direct function of the number of matching or identical positions, e.g., if half (e.g., 5 positions in a polymer 10 subunits in length) of the positions in two polypeptide sequences are identical, then the two sequences are 50% identical; if 90% of the positions, e.g., 9 of 10, are matched, the two sequences share 90% sequence identity.
- Methods of sequence analysis and alignment for the purpose of comparing the sequence identity of two comparison sequences are well known by those skilled in the art.
- substantially identical is meant sequences that differ by no more than 10% of the residues, and only by conservative amino acid substitutions such as those shown in Table 1, or non- conservative amino acid substitutions, deletions, or insertions that do not appreciatively diminish the polypeptide's biological activity, e.g., an insertion of amino acids at the junction of the core protein and surface protein sequences that has no appreciative effect on biological activity.
- Biological activity refers to the ability of a mutant polypeptide to inhibit hepadnavirus replication, and can be measured by the assays described below.
- nucleic acid is meant deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) .
- the methods, nucleic acids, and polypeptides of the invention can be used to inhibit hepadnaviral replication in a mammal, e.g., as an effective therapy for treating individuals with a persistent HBV infection, or as a means of reducing the risk of hepatocellular carcinoma in an infected animal.
- Polypeptides of the invention can be administered to an infected animal either directly or by gene therapy techniques.
- the screening methods of the invention are simple, rapid, and efficient assays designed to identify polypeptides with anti-hepadnaviral activity.
- FIG. 1 is a schematic illustration of the structural organization of "wild type" and mutant hepadnavirus constructs.
- Fig. 2 is an autoradiographic image of an agarose gel, showing a Southern blot analysis of core particle DNA that was extracted from HuH-7 cells five days post transfection and probed with full length 32 P-labeled WHV DNA.
- Fig. 3 is an autoradiographic image of an agarose gel, showing a Southern blot analysis of core particle associated viral DNA that was extracted from HuH-7 cells five days after transfection and probed simultaneously with the two full length 32 P-labeled WHV and HBV DNA probes.
- Fig. 4 is an autoradiographic image of an agarose gel, showing a Southern blot analysis of core particle associated viral DNA that was extracted from HepG2 cells five days after transfection and probed with full length 32 P-labeled HBV DNA.
- Fig. 5 is an autoradiographic image of a polyacrylamide gel showing a RNase protection assay.
- Fig. 6 is an autoradiographic image of an agarose gel showing a Southern blot analysis of the anti-viral effect of dominant negative core mutants on "wild type" HBV replication during transient transfection in HuH-7 cells.
- Fig. 7 is an autoradiographic image of a SDS- polyacrylamide gel showing a Western blot analysis of HepG2 cell lysates probed with anti-HBc antibodies.
- Fig. 8 is an autoradiographic image of an agarose gel showing a Southern blot analysis of the effect of a dominant negative core mutant on replication of HBV in Hep-G2 2215 cells.
- Fig. 9 is an autoradiographic image of an agarose gel showing a Southern blot analysis of cytosol-derived nucleocapsids from transfected LMC cells hybridized with a full length DHBV DNA probe.
- Fig. 10 is an illustration of the nucleic acid sequence of the pCN4 plasmid insert (SEQ ID NO: 1) and the corresponding translated amino acid sequence (SEQ ID NO: 2).
- Fig. 11 is an illustration of the nucleic acid sequence of the pHBV DN plasmid insert (SEQ ID NO: 3) and the corresponding translated amino acid sequence (SEQ ID NO: 4).
- Fig. 12 is an illustration of the nucleic acid sequence of the pHBV DN AA plasmid insert (SEQ ID NO: 5) and the corresponding translated amino acid sequence (SEQ ID NO: 6) .
- Fig. 13 is an illustration of the nucleic acid sequence of the pHBV DN BB plasmid insert (SEQ ID NO: 7) and the corresponding translated amino acid sequence (SEQ ID NO: 8) .
- Fig. 14 is an illustration of the nucleic acid sequence of the pDHBV BK plasmid insert (SEQ ID NO: 9) and the corresponding translated amino acid sequence (SEQ ID NO: 10) .
- Fig. 15 is an illustration of the nucleic acid sequence of the HBV core protein (SEQ ID NO: 11) and the corresponding translated amino acid sequence (SEQ ID NO: 12).
- Fig. 16 is an illustration of the nucleic acid sequence of the HBV core protein (SEQ ID NO: 13) and the corresponding translated amino acid sequence (SEQ ID NO: 14).
- Applicants have observed that replication of a wild type hepadnavirus is reduced when it is co- transfected with a nucleic acid construct encoding a truncated core protein, or a core-surface fusion protein.
- the truncated core protein alone or in combination with the surface protein component, has a deletion of at least three amino acids from the carboxyterminal end. Viral replication is reduced by as much as 90-95% without detectable toxic effects on the host cell.
- HBV mutant core-surface fusion protein as a retroviral insert substantially inhibits HBV viral DNA production in cells that previously had continuously produced all viral replicative intermediates and infectious virions.
- An adenoviral-based plasmid that encodes the same mutant core-surface fusion protein also inhibits HBV replication following transient cotransfection in HCC cells.
- Plasmid Constructs The parental plasmid pCMW82 was used to generate a series of constructs expressing WHV core proteins with an altered carboxyterminal region. Plasmid pCMW82 expresses the "wild type" WHV pregenome under the control of the cytomegalovirus immediate-early (CMV IE) promoter (Seeger et al., J. Virol . , ⁇ 3_, 4665- 4669, 1989). The pHBV plasmid carries the HBV pregenome under the control of the CMW IE promoter. These plasmids direct the synthesis of complete virions in tissue culture cells. The first nucleotide of the precore open reading frame was designated as nucleotide number 1 in the WHV genome.
- CMV IE cytomegalovirus immediate-early
- Fig. 1 The structural organization of "wild type” and mutant WHV, HBV, and DHBV core plasmid constructs are depicted in Fig. 1.
- the white boxes represent the open reading frame (ORF) used for constructing core mutants. Numbers at the boundaries of each ORF refer to the amino acids in the "wild type” or mutant proteins. Dotted lines represent deleted sequences. Solid and hatched boxes correspond to mutant core proteins expressed from WHV and HBV, respectively. Shaded bars refer to DHBV. The shaded hatched bars refer to the polymerase gene. Except for the "wild type" constructs pCMW82 and pCMW- DHBV, all other constructs are incapable of replication because of deletions in genes that overlap the truncated portions of the core protein. The * refers to a stop codon introduced by a frame shift mutation.
- Fig. 1 The constructs shown in Fig. 1 were produced by complete digestion with the appropriate restriction enzyme. This was followed by subsequent incubation at 30°C for 20 min. in the presence of the Klenow fragment of DNA polymerase I and deoxyribonucleotide triphosphates, which filled in the 3' recessed DNA ends. Plasmids were then ligated with T4 DNA ligase. The 3' protruding ends were filled in by incubation with the Klenow fragment of DNA polymerase I in the absence of deoxyribonucleotide triphosphates at 37°C for 15 min. This eliminated protruding ends. Deoxyribonucleotide triphosphates were then added and incubation was carried out at 30 ⁇ C for 20 min. (Sambrook et al.. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989) .
- Constructs containing mutations in sequences encoding the core protein were obtained as follows: 1) pCNl: To make the plasmid pCNl the WHV core gene was digested with the restriction enzyme SstI at nucleotide (nt) 310, incubated with Klenow DNA polymerase, and reclosed with T4 DNA ligase. This introduced a frame shift mutation at nt. 306 in the WHV core gene, thereby creating a stop codon at nt. 317. This mutation produces a 74 amino acid carboxyterminal truncated core protein, leaving intact the rest of the viral coding regions.
- pCN2 To make pCN2 the WHV parental plasmid was digested with the restriction enzymes Bglll (nt. 601 in the core gene) and Smal, the latter being located in the downstream multiple cloning site of the vector. The intervening viral genes were separated by gel electrophoresis, and the DNA ends were filled in with Klenow DNA polymerase and ligated with T4 DNA ligase. This WHV core gene has 12 amino acids deleted at the carboxyterminus and is fused to a three amino acid heterologous extension from the plasmid vector.
- Bglll nt. 601 in the core gene
- pCN3 To make the plasmid pCN3, the wild type plasmid pCMW82 was digested with the restriction enzymes Bglll and SacII (position 2983 in the WHV X gene) , the intervening viral DNA fragment was removed, and ends were filled in and ligated. The resulting plasmid construct encodes a 171 amino acid core protein fragment fused in-frame with the X protein at amino acid 31. 4) pCN4: The plasmid pCN4 was produced by a Bglll-MscI (position 1826) fragment excised from pCMW82 and blunted by Klenow DNA polymerase.
- Bglll-MscI position 1826
- the plasmid was ligated to join the WHV 171 amino acid core protein as an in-frame fusion protein with amino acid 47 of the WHV small surface protein.
- pCN5 The plasmid pCN5 was produced by removing the DNA fragment SstI (pos. 306)-BspEI (pos. 519) from pCN4, and blunting the ends with Klenow DNA polymerase and T4 DNA ligase. This introduced a WHV core in-frame deletion between amino acids 74 and 145.
- Plasmid pCN6 expresses the first 171 amino acids of the WHV core protein fused in- frame with the HBV small surface protein at amino acid 51.
- the HBV numbering system designates the unique EcoRI site as nucleotide 1.
- Construct pHBV DN was generated by digesting pCMW82 at nt. 601 of the core gene with Bglll, and blunting the DNA end with Klenow DNA polymerase. A second cut was performed with Pvul in the ampicillin resistance gene of the carrier plasmid, and the Bglll-Pvul DNA fragment was removed by fractionation on an agarose gel. The HBV MscI (pos. 299)-Pvul (in the ampicillin resistance gene of pHBV) fragment was ligated to the blunted Bglll-Pvul fragment.
- the pCN6 fragment from the SnaBI site (which cuts in the CMV promoter of the carrier plasmid) to the BspEI site (pos. 519 in the WHV) was removed and substituted with the same SnaBI-BspEI (pos. 2327) fragment from pHBV.
- the HBV core protein was fused in-frame to amino acid 144 of the WHV core protein.
- the resulting pHBV DN therefore encodes, in the hinge between the deleted core and surface proteins, five amino acids derived from the WHV core protein (GGARA) . These five amino acids were not present in the subtype HBV core protein. The carboxyterminal 20 amino acid of the WHV core protein are conserved in HBV.
- Two additional plasmids were derived from pHBV and called pHBV AA and pHBV BB.
- pHBV DN AA pHBV was partially digested with the restriction enzyme Aval (nt. 2431) , and then partially digested with Avrll (nt. 176) . The resulting DNA ends were blunted by adding Klenow DNA polymerase and nucleotide triphosphates.
- the DNA ends were ligated with T4 ligase.
- the resulting plasmid pHBV DN AA encodes the HBV core protein fused in frame at amino acid 179 with the surface protein (encoded by the "S gene") at amino acid 8.
- the plasmid pHBV BB was made by performing two sequential partial digestions with the enzymes Bglll and BamHI.
- the DNA ends were ligated with T4 ligase.
- the pHBV BB plasmid expresses the HBV core protein fused in frame at amino acid 175 with the surface protein at amino acid 112. The correct design of the constructs was confirmed by restriction digest mapping and DNA sequence analysis.
- Plasmid DNAs were purified by the alkali lysis procedure followed by sedimentation through a cesium chloride-ethidium bromide density gradient. As a result of these viral gene manipulations the above plasmid constructs produce replication defective WHV genomes. Plasmid pCNl expresses a truncated core protein that is unable to assemble into functional nucleocapsids. All other constructs contain inactivating deletions in the polymerase gene. Another plasmid, designated pRHBBE, was constructed using the polylinker of the plasmid pBS SK(+) (Stratagene) , which allows for viral gene transcription from the T7 promoter to make a HBV-specific 276 nt antisense RNA.
- Constructs expressing DHBV dominant negative proteins were derived from the plasmid pCMV DHBV (Wu et al., J. Virol . , .65., 2155-2163, 1991), which expresses the DHBV pregenome under the control of the CMV promoter.
- Construct pSK contains a deletion between the SphI site (position 2843 in the core gene; this numbering system is arbitrarily initiated with the nucleotide GAATTC of the unique EcoRI site) and the Kpnl site (position 1290, in the S gene) . The intervening fragment was separated by agarose gel electrophoresis. The ends of the larger DNA fragment were blunted by Klenow DNA polymerase and religated.
- This construct expresses, under the control of the CMV promoter, a protein composed of the first 66 amino acids of the DHBV core protein fused in frame to amino acid five of the DHBV surface protein.
- Construct pBK contains a deletion between the Bglll site (position 391 in the core gene) and the Kpnl site (position 1290 in the S gene) .
- the intervening fragment was separated by agarose gel electrophoresis and the ends of the larger DNA fragment were filled in and blunted by the Klenow DNA polymerase. The ends were then religated.
- the resulting construct expresses, under the control of the CMV promoter, a protein composed of the first 257 amino acids of the DHBV core protein (five amino acids are missing from the carboxyterminus) , fused in frame to the fifth amino acid of the DHBV surface protein.
- the pCMV DHBV was linearized by cutting at the Kpnl site (position 1290 of the S gene) . The DNA ends were blunted with the Klenow DNA polymerase reaction and the fragment was religated.
- the resulting construct has a frame-shift mutation so that the DHBV polymerase pK gene and the pre-S and S genes have a termination site a few nucleotides downstream from the Kpnl site.
- construct pK thus expresses, under the control of the CMV promoter, the full length core protein, but none of the envelope proteins apart from a truncated pre-S protein.
- a frameshift mutation that occurs in the polymerase gene renders the other constructs carrying the deletions described above replication defective.
- Construct pNX contains a deletion between the Nsil site (position 2845 in the core gene) and the Xhol site (position 1212 in the pre-S gene) .
- the intervening fragment was separated by agarose gel electrophoresis.
- the ends of the larger DNA fragment were blunted and filled in with Klenow DNA polymerase, followed by religation of the fragment to itself.
- This construct expresses, under the control of the CMV promoter, the first 68 amino acids of the DHBV core protein fused in frame to amino acid 437 of the carboxyterminus of the polymerase gene.
- Retroviral constructs The HBV core-surface fusion gene encoded by pHBV DN was PCR amplified with oligonucleotides containing at their 5' ends a Sail restriction enzyme recognition site.
- the antisense primer contained a recognizable Flag epitope (Kodak) .
- the PCR product was gel purified, digested with Sail, and cloned in the retroviral pBabe Puro vector (Morgenstern et al., Nucl . Acids Res . , 18:3587-96, 1990) at its Sail site.
- the design of the resulting pBP HBV DN vector was confirmed by sequence analysis.
- Another cell line derived from LMH and named D2, was created by stably transfecting a head-to- tail DHBV dimer that produces infectious DHBV particles. These cells were grown in DMEM and 10% FCS and transfected with the various dominant negative core mutant constructs as described above.
- Infection of the HepG2 2215 Cell Line Infection of the HepG2 2215 cell line by recombinant retroviruses was accomplished following a standard protocol for producing retroviral stocks and for infecting tissue culture cells (Miller et al., Biotechniques , 1_, 980-990, 1989; Miller, et al.. Methods in Enzymology. 217. 581, 1993) .
- WHV and HBV DNA replication were assayed by Southern blot analysis of DNA that had been extracted from intracellular core particles. The procedure for isolation of core particles was previously described in detail (Pugh et al., J. Virol . , e>2., 3513-3516, 1988). DNA fractionation on agarose gels was performed under alkali conditions and the DNA was transferred onto a nylon membrane for Southern blot analysis (Hybond N, Amersham International, Little Chalfont, UK) .
- Prehybridization and hybridization reactions were carried out at 65°C in 6X SSC solution (IX SSC is 150 mM NaCl, 15 mM Na 3 Citrate) , 5X Denhardt's solution (100X is 2% w/v BSA, 2% w/v Ficoll, 2% w/v polyvinyl pirollidone) , and 0.5% SDS.
- WHV and HBV DNAs were detected by hybridization with randomly primed 32 p- labeled full length WHV or HBV DNA (Multiprime DNA
- the membranes were washed twice for 15 min. each at 65°C in IX SSC, 0.1% SDS, and were then washed once more at 65°C in 0.1X SSC, 0.1% SDS.
- the nylon membranes were then autoradiographed at -70°C, using intensifying screens and Kodak films. Signal intensities on the nylon sheets were quantitated by a computer assisted scanning system (Ambis Quantprobe System version 3.0).
- RNA was extracted from a 100 mm dish by lysis of cells in 1 ml of solution D (4 M guanidinium thiocyanate, 25 mM NaCitrate, pH 7.0, 0.5% sarcosyl, 0.1 M 2- mercaptoethanol) as described (Chomczynski et al., Anal. Biochem.. 168. 156-159, 1987). Encapsidated viral RNA was extracted from core particles by lysis in 200 ml of solution D and the volumes were adjusted accordingly as described (Roychoury et al., supra) .
- the encapsidated viral RNA was digested with 16 U RNase-free DNase RQl DNase (Promega, Madison, WI) at 37°C for 15 min. , followed by phenol-chloroform extraction and ethanol precipitation, before undergoing the RNase protection assay.
- RNA probe was derived from the plasmid pRHBBE, a derivative of the pBluescript SK(+) , which includes the 280 bp HBV fragment BamHI (pos. nt
- RNA probe contained approximately 50 nt of plasmid sequences that were not protected by the HBV specific RNA. Labeled RNA was synthesized as follows: 0.5 ⁇ g of pRHBBE was cut by BamHI and then transcribed by T7 RNA polymerase (Promega, Madison, WI) in the presence of ⁇ - 32 P UTP (100 ⁇ Ci at 400 Ci/mM, New England Nuclear, Boston, MA) .
- the antisense RNA probe recognized pregenomic RNA and the 2.4 pre-Sl mRNA derived from "wild type" HBV, but did not recognize transcripts derived from pHBV DN.
- Hybridization after denaturation at 95°C for 3 min., was performed in 20 ⁇ l on 2 ⁇ g of total RNA or encapsidated pregenomic RNA derived from half of a 100 mm plate at 42°C overnight in a solution of 80% formamide, 100 mM NaCitrate pH 6.4, 300 mM NaAcetate pH 6.4, and ImM EDTA.
- RNase digestion was carried out with RNase A (0.5U) and RNase Tl (20 U) at 37°C for 30 min. Fragments protected by RNase digestion were separated on a denaturing 6% polyacrylamide gel (Seguagel 6%, National Diagnostics, Atlanta, GA) .
- HBcAg antigenicity was detected by incubation of the membrane with polyclonal antibodies prepared in rabbits against recombinant HBcAg (Dake Co., Carpinteria, CA) at a 1:250 dilution in the above solution for one hour at 20°C.
- the filter was washed at 20°C in PBS, 0.5% Tween-20 with three successive changes of solution. Bound antibody was detected using the chemiluminescence method (ECL, Amersham International, Little Chalfont, UK) using peroxidase labeled goat anti-rabbit antibodies. The filter was exposed to Kodak films for 5-20 seconds.
- WHV core mutant plasmids were tested for the ability to inhibit wild type WHV DNA replication in HuH-7 cells.
- Fig. 2 shows a Southern blot analysis of core particle DNA that was extracted from HuH-7 cells five days post transfection and probed with full length 32 P labeled WHV DNA.
- Lane M contains 32 P 5' end labeled lambda Hindlll molecular weight markers.
- the HuH-7 cells were transfected with: lane 1, pCMW82; lane 2, pCMW82 and pCN4; lane 3, pCMW82 and pCNl; lane 4, pCMW82 and pCN2; lane 5, pCMW82 and pCN3; and lane 6, pCMW82 and pCN5.
- Each lane was loaded with one-half of the core associated viral DNA, which had been extracted from a 100 mm tissue culture dish of HuH-7 cells.
- Fig. 3 shows a Southern blot analysis of core particle associated viral DNA extracted from HuH-7 cells five days after transfection. The blots were probed simultaneously with full length 32 P labeled WHV and HBV DNA probes. Lane M contains 32 P 5' end labeled lambda Hindlll molecular weight markers.
- Core particle associated viral DNA was extracted from cells transfected with: lane 1, pCMW82; lane 2, pCMW82 and pCN4; lane 3, pCMW82 and pCN6; lane 4, pHBV; lane 5, pHBV and CN4; and lane 6, pHBV and pCN6.
- Each lane was loaded with one-half of the core particle associated DNA that had been extracted from a 100 mm tissue culture dish of HuH-7 cells.
- a chimeric construct expressing WHV core-HBV small surface fusion protein was produced.
- This plasmid designated pCN6, reduced "wild type" WHV replication by 85%, an inhibitory effect comparable to the original parental construct pCN4. Like pCN4, pCN6 does not inhibit HBV replication (Fig 3, lane 6). It was concluded that the WHV core-small surface fusion protein encoded by pCN4 exerts a species-specific inhibitory effect.
- HuH-7 cells were co-transfected at various ratios of CMW82 to pCN4 using 10 ⁇ g of pCMW82.
- the total amount of transfected DNA was kept constant (20 ⁇ g) by adding unrelated sonicated salmon sperm DNA.
- the results of these experiments indicate that when pCN4 was diluted by 10 and 50 fold, there was still a 66% and 20% inhibition of "wild type” WHV replication, respectively. Interference with viral replication occurs even in the presence of an excess of "wild type” core protein.
- Dominant negative core mutant polypeptides are not toxic to HCC cells. To insure that the mutant plasmids were neither affecting the efficiency of DNA uptake by HuH-7 cells during transfection, nor inducing a cytopathic effect, each 100 mm plate had a 10 mm cover slip containing cells grown under the same conditions. The cells were investigated by immunocytochemistry utilizing the protocol of Jilbert et al. (J. Virol . , 66. 1377-1378, 1992). Core protein expression was detected with polyclonal antibodies prepared against either WHV or HBV recombinant core proteins.
- WHcAg Approximately one percent of the HuH-7 cells were transfected with the "wild type" WHV plasmid, as demonstrated by diffuse cytoplasmic staining for WHcAg in cells harvested five days post transfection. After transfection of cells with pCN4 alone, a punctate distribution of WHcAg in the perinuclear region was observed. The same staining pattern was obtained when the dominant negative core mutant constructs were co-transfected with "wild type” pCMW82. The total number of HBcAg positive cells did not vary under these conditions. The mutant core expressing plasmids did not inhibit "wild type" viral DNA uptake during the transfection process and were not toxic to HuH-7 cells.
- RNA was extracted from HuH-7 cells that had been transfected with the plasmids pCMW82 alone, pCMW82 and pCN4 together, or pCN4 alone.
- the RNA was probed with a Bglll-BstXI WHV DNA fragment that specifically recognized the pregenomic RNA but not the pCN4 transcripts.
- the results demonstrated no change in the level of "wild type" WHV pregenomic RNA transcription from pCMW82 in the presence of pCN4.
- pHBV DN was designed to be the molecular HBV-derived equivalent of pCN4. Plasmid pHBV DN was co-transfected with "wild type” pHBV into HuH-7 and HepG2 cells. It inhibited "wild type” HBV DNA replication by 90% (Fig. 4).
- Fig. 4 shows a Southern blot analysis of core particle associated viral DNA extracted from HepG2 cells five days after transfection. The blot was probed with full length 32 P labeled HBV DNA. Lane M contains 32 P 5' end labeled lambda Hindlll molecular weight markers. Lane 1 contains 3.2 kb linear HBV DNA (10 pg) . The remaining lanes show core particle associated viral DNA extracted from cells transfected with pHBV (lane 2) ; or PHBV and pHBV DN (lane 3).
- pHBV DN AA and pHBV DN BB were assayed in the same manner, for the purpose of mapping which regions of the core protein and of the surface protein were necessary for inhibition.
- the construct pHBV DN AA was at least as potent an inhibitor as pHBV DN, whereas pHBV DN BB was less inhibitory than pHBV DN.
- Fig. 5 is a Southern blot analysis illustrating the antiviral effects of the pHBV DN AA and pHBV DN BB dominant negative core mutants on "wild type" HBV replication during transient transfection experiments in HuH-7 cells.
- the pCMV-HBV lane shows the level of "wild type" HBV replication in HUH-7 cells.
- the dominant negative mutant pHBV-DN reduced wild type replication by 95%.
- this construct was placed in a vector containing the adenovirus sequences necessary for producing a recombinant adenovirus vector (Ad HBV DN) , there was an 80% decrease in HBV replication.
- Ad HBV DN construct was placed in a retroviral vector (e.g., pBP HBV DN) , there was a 90-95% reduction in HBV replication.
- Lane 1 contains 2 ⁇ g of total RNA from HepG2 cells transfected with pHBV; lane 2 contains 2 ⁇ g of total RNA from HepG2 cells transfected with pHBV and pHBV DN; lane 3 contains 2 ⁇ g of total RNA from HepG2 cells transfected with pHBV DN alone (the BamHI-EcoRI fragment is missing in this construct) .
- the remaining lanes show RNA that was extracted from HepG2-derived core particles and then probed as in lanes 1-3. Each lane was loaded with half of the core associated RNA extracted from a 10 cm dish.
- Lane 4 contains core particle associated RNA from cells transfected with pHBV.
- Lane 5 contains core particle associated RNA from cells transfected with pHBV and pHBV DN.
- Lane 6 contains core particle associated RNA from cells transfected with pHBV DN alone. There was a 90% reduction in encapsidation of "wild type" pregenomic RNA when pHBV DN was co- transfected with the wild type HBV DNA expressing plasmid, whereas no significant reduction in viral RNA was observed in experiments performed with total cellular RNA.
- the riboprobe used in this experiment protects pregenomic and pre-Sl transcripts, both of which were absent in the pHBV DN transfected cells.
- Wild type pregenomic viral RNA is incapable of being encapsidated in the presence of mutant core protein because of inefficient core particle assembly.
- Cell lysates derived from HepG2 cells previously transfected with pHBV alone, pHBV and pHBV DN together, and pHBV DN alone were sedimented on a 20% w/v sucrose cushion for one hour at 500,000 g. Under these experimental conditions non-particulate core protein and HBeAg were left in solution (Zhou et al., supra) .
- the pellet was analyzed for core protein by 12.5% SDS-PAGE electrophoresis, and analyzed on a Western blot using polyclonal anti-HBc antibodies as probes (Fig. 7) .
- the viral core particles were derived from: lane 1, cells transfected with pHBV; lane 2, cells transfected with pHBV and pHBV DN; lane 3, cells transfected with pHBV DN alone; lane 4, HepG2 2215 cells (positive control).
- Lane 5 contains 100 ⁇ g of cell lysate in RIPA buffer not subjected to ultracentrifugation and extracted from HepG2 2215 cells to show enrichment of core particles by the pelleting technique (positive control) .
- the protein in lane 6 was derived from the pellets of untransfected HepG2 cells (negative control). A protein band of 21.5 kd, corresponding to the intact "wild type" HBV core protein, was detected only in the pellet derived from HepG2 cells transfected with pHBV.
- HBV core dominant negative mutant HBV DN can make hepatoma cell lines resistant to HBV replication.
- the HBV DN coding sequence was cloned into the retroviral vector pBabe Puro (pBP) , which contains a puromycin selectable marker.
- the resulting vector is named pBPHBV DN.
- Recombinant retroviral stocks were obtained after transfecting pBPHBV DN into the packaging cell line PA317. The stocks were then used to infect HepG2 and HepG2 2215 cell lines.
- the HepG2 2215 cells constitutively produce wild type HBV virions due to the stable integration of a head to tail dimer of HBV.
- HBV DNA was purified from the core particles and analyzed by Southern blot.
- HepG2 2215 transduced by the pBP HBV DN vector showed a 90% reduction in HBV replication when compared to HepG2 2215 cells transduced by the pBP vector (Fig. 8) .
- This result demonstrates a striking reduction of HBV replicative intermediates in core particles, even in a cell line that constitutively expresses all the viral gene products and replicative forms of the virus.
- the Flag tagged dominant negative form of the HBV DN sequence was also cloned into the adenoviral vector pAdBglll to generate the vector pAdHBV DN.
- This vector contains a multiple cloning site flanked by the CMV El promoter and by adenovirus 5 sequences.
- the adenovirus 5 sequences allow homologous recombination and reconstitution of a recombinant replication incompetent adenovirus after cotransfection in 293 cells (Graham et al., the Human press, Vol 7. 109-128, 1991).
- the plasmid pAdHBV DN was then introduced, along with pHBV, into HCC cells by transient transfection, inhibiting HBV replication by 80% (Fig. 5) .
- Adenoviral vectors such as pAd HBV DN can be used to generate a replication incompetent adenovirus by homologous recombination, and can express the HBV DN polypeptide in the liver.
- DHBV replication was obtained by co- transfecting pCMV DHBV with the plasmid pBK.
- the pBK plasmid encodes a DHBV core protein which lacks the last carboxyterminal five amino acids, fused to a surface protein which lacks the aminoterminal first four amino acids.
- plasmid pSK plasmid pSK
- pNX Pol gene product
- pSK pre-S gene product
- LMC 9 is a Southern Blot analysis of cytosolic derived nucleocapsid DNA from transfected LMC cells, hybridized to a full length DHBV DNA probe.
- LMC cells were transfected with 10 ⁇ g of pCMV DHBV together with 10 ⁇ g of mutant plasmids pSK (lane 2) , pBK (lane 3) , pSK (lane 4, the same as lane 2) , pK (lane 5) , or pNX (lane 6) .
- the last lane contains the cytosolic derived nucleocapsid DNA from a LMC cell line stably transfected with a head-to-tail DHBV dimer as a positive control. Replication of "wild type" DHBV was inhibited by the dominant negative core mutant construct BK.
- the mutant polypeptides of the invention can be provided exogenously to a target cell of an animal suspected of harboring a hepadnavirus infection by any appropriate method, for example by oral, parenteral, transdermal, or transmucosal administration.
- the mutant polypeptide can be administered in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels or liposomes.
- Therapeutic doses can be, but are not necessarily, in the range of 0.01 - 100.0 mg/kg body weight, or a range that is clinically determined to be appropriate by those skilled in the art.
- polypeptides useful in a method of the invention, or as candidate agents in a method of the invention can be purified using conventional methods of protein isolation known to one skilled in the art. These methods include, but are not limited to, precipitation, chromatography, immunoadsorption, or affinity techniques (see, e.g.. Scopes, R. Protein Purification: Principles and Practice. 1982 Springer Verlag, NY) .
- the polypeptide can be purified from starting material that is derived from a genetically engineered cell line.
- One useful method of purification involves expressing the polypeptide as a fusion protein encoded by a glutathione- S-transferase vector, purifying the resulting fusion protein by GST-GSH affinity chromatography, and removing the GST portion of the fusion polypeptide by thrombin cleavage.
- a synthetic mutant polypeptide can be prepared by automated peptide synthesis (see, e.g., Ausubel et al., eds. Current Protocols in Molecular Biology. John Wiley & Sons, publ. NY. 1987, 1989; Sambrook et al. (1989) , Molecular Cloning; A Laboratory Manual (2d ed.), CSH Press).
- Therapeutic administration of a mutant polypeptide can also be accomplished using gene therapy techniques.
- a nucleic acid that included a promoter operatively linked to a sequence encoding a polypeptide of the invention is used to generate high-level expression of the polypeptide in cells transfected with the nucleic acid.
- Gene transfer can be performed ex vivo or in vivo.
- cells can be removed from the body of the patient, transfected with the nucleic acid encoding the mutant polypeptide, and returned to the patient's body.
- the nucleic acid can be administered in vivo, by transfecting the nucleic acid into target cells (e.g., hepatocytes) so that the mutant polypeptide is expressed in situ .
- target cells e.g., hepatocytes
- the nucleic acid molecule is contained within a non-replicating linear or circular DNA or RNA molecule, or within an autonomously replicating plasmid or viral vector, or may be integrated into the host genome.
- Any vector that can transfect a cell can be used in the methods of the invention.
- Preferred vectors are viral vectors, including those derived from replication- defective hepatitis virus (e.g., HBV and HCV) , retrovirus (see, e.g., WO89/07136; Rosenberg et al., N. Eng. J. Med. 323(9) :570-578, 1990; Miller et al. , 1993 supra) , adenovirus (see, e.g., Morsey et al., J.
- viral vectors include those modified to target a specific cell type (see, e.g., Kan et al. WO 93/25234; Kasahara et al. Science, 266:1373-76, 1994; Dornburg et al. WO 94/12626; Russell et al. WO 94/06920) .
- Methods for constructing expression vectors are well known in the art (see, e.g., Molecular Cloning: A Laboratory Manual, Sambrook et al., eds., Cold Spring Harbor Laboratory, 2nd Edition, Cold Spring Harbor, New York, 1989) .
- Appropriate regulatory sequences can be inserted into the vectors of the invention using methods known to those skilled in the art, e.g., by homologous recombination (Graham et al., J. Gen . Virol . 3_6:59-72, 1977), or by other appropriate methods (Sambrook et al., eds., supra) .
- Promoters are inserted into the vectors so that they are operatively linked 5' to the nucleic acid sequence encoding the mutant polypeptide.
- Any promoter that is able to initiate transcription in a target cell can be used in the invention.
- non-tissue specific promoters such as the cytomegalovirus (DeBernardi et al., Proc.
- mice metallothionine I gene Hammer, et al., J. Mol. Appl. Gen. 1:273-288, 1982
- HSV thymidine kinase McKnight, Cell, 31:355-365, 1982
- SV40 early Benoist et al., Nature, 290:304-310, 1981
- Preferred promoters for use in the invention are hepatocyte-specific promoters, the use of which ensures that the mutant polypeptides are expressed primarily in hepatocytes.
- Preferred hepatocyte-specific promoters include, but are not limited to the albumin, alpha- fetoprotein, alpha-1-antitrypsin, retinol-binding protein, and asialoglycoprotein receptor promoters. Additional viral promoters and enhancers, such as those from herpes simplex virus (types I and II) , hepatitis virus (Types A, B, and C) , and Rous sarcoma virus (RSV; Fang et al., Hepatology 10:781-787, 1989), can also be used in the invention.
- herpes simplex virus types I and II
- hepatitis virus Types A, B, and C
- Rous sarcoma virus Rous sarcoma virus
- the mutant polypeptides of the invention, and the recombinant vectors containing nucleic acid sequences encoding them, may be used in therapeutic compositions for preventing or treating HBV infection.
- the therapeutic compositions of the invention may be used alone or in admixture, or in chemical combination, with one or more materials, including other mutant polypeptides or recombinant vectors, materials that increase the biological stability of the oligonucleotides or the recombinant vectors, or materials that increase the ability of the therapeutic compositions to penetrate hepatocytes selectively.
- the therapeutic compositions of the invention can be administered in pharmaceutically acceptable carriers (e.g., physiological saline), which are selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers, as well as pharmaceutical necessities for use in pharmaceutical formulations, are described in Remington 's Pharmaceutical Sciences, a standard reference text in this field.
- compositions of the invention can be administered in dosages determined to be appropriate by one skilled in the art.
- An appropriate dosage is one which effects a reduction in a disease caused by HBV infection. It is expected that the dosages will vary, depending upon the pharmacokinetic and pharmacodynamic characteristics of the particular agent, and its mode and route of administration, as well as the age, weight, and health (including renal and hepatic function) of the recipient; the nature and extent of the disease; the frequency and duration of the treatment; the type of, if any, concurrent therapy; and the desired effect. It is expected that a useful dosage contains between about 0.1 to 100 mg of active ingredient per kilogram of body weight. Ordinarily a dosage of 0.5 to 50 mg, and preferably, 1 to 10 mg of active ingredient per kilogram of body weight per day given in divided doses, or in sustained release form, is appropriate.
- compositions of the invention may be administered to a patient by any appropriate mode, e.g., parenterally, as determined by one skilled in the art. Alternatively, it may by necessary to administer the treatment surgically to the target tissue. The treatments of the invention may be repeated as needed, as determined by one skilled in the art.
- the invention also includes any other methods which accomplish in vivo transfer of nucleic acids into target cells.
- the nucleic acids may be packaged into liposomes, non-viral nucleic acid-based vectors, erythrocyte ghosts, or microspheres (microparticles; see, e.g., U.S. Patent No. 4,789,734; U.S. Patent No. 4,925,673; U.S. Patent No. 3,625,214; Gregoriadis, Drug Carriers in Biology and Medicine, pp. 287-341 (Academic Press, 1979)).
- delivery of mutant polypeptides be accomplished by direct injection of their nucleic acid coding sequences into target tissues, for example, in a calcium phosphate precipitate or coupled with lipids, or as "naked DNA".
- Mutant core polypeptides and core-surface fusion proteins of the invention can be tested for their ability to inhibit hepadnavirus replication in an animal model.
- candidate polypeptides can be injected into an animal that is infected with a hepadnavirus, e.g., a woodchuck, duck, or ground squirrel harboring its respective hepatitis B virus variants (see, e.g.. Mason et al., J. Virol . 36:829, 1980; Schodel et al., in Molecular Biology of hepatitis B virus. CRC press, Boca Raton, p. 53-80, 1991; Summers et al., Proc. Natl . Acad. Sci .
- Candidate polypeptides can also be analyzed in transgenic animal strains developed for the purpose of studying hepadnaviral gene expression (see, e.g., Babinet et al.. Science, 230:1160- 63, 1985; Burk et al., J. Virol. 62:649-54, 1988; Chisari et al.. Science 230:1157-60, 1985; Chisari, in Current Topics in Microbiology and Immunology, p. 85-101, 1991) .
- Candidate polypeptides of the invention can also be tested in animals that are naturally infected with HBV, e.g., in chimpanzees, by administering the polypeptides, or the nucleic acids encoding them, to the animal by one of the methods discussed above, or by other standard methods.
- TTA ACT AAA TTG ATA GCT TGG ATG AGC TCT AAC ATA ACT TCT GAA CAA 240 Leu Thr Lys Leu He Ala Trp Met Ser Ser Asn He Thr Ser Glu Gin 65 70 75 80
- TGT TGT TGT TTA AAA CCT ACG GCA GGA AAT TGC ACT TGT TGG CCC ATC 816 Cys Cys Cys Leu Lys Pro Thr Ala Gly Asn Cys Thr Cys Trp Pro He 260 265 270
- GGC GCG CTA AAG TTC AGG CAA CTC TTG TGG TTT CAC ATT TCT TGT CTC ACT 336 Gly Leu Lys Phe Arg Gin Leu Leu Trp Phe His He Ser Cys Leu Thr 445 450 455
- TCT CTC AAT TTT CTA GGG GGA ACT ACC GTG TGT CTT GGC CAA AAT TCG 672 Ser Leu Asn Phe Leu Gly Gly Thr Thr Val Cys Leu Gly Gin Asn Ser 560 565 570 575
- GCT TTA ACG TTT GGA CTT TCA CTT ATA TGG ATG ACT TCC TCC TCT GCC 1200 Ala Leu Thr Phe Gly Leu Ser Leu He Trp Met Thr Ser Ser Ser Ala 675 680 685
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62844/96A AU699398B2 (en) | 1995-06-20 | 1996-06-20 | Inhibition of hepatitis B replication |
EP96921695A EP0833668A4 (en) | 1995-06-20 | 1996-06-20 | Inhibition of hepatitis b replication |
JP9503930A JPH11508766A (en) | 1995-06-20 | 1996-06-20 | Inhibition of hepatitis B replication |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1781495P | 1995-06-20 | 1995-06-20 | |
US60/017,814 | 1995-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997000698A1 true WO1997000698A1 (en) | 1997-01-09 |
Family
ID=21784687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/010602 WO1997000698A1 (en) | 1995-06-20 | 1996-06-20 | Inhibition of hepatitis b replication |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020035081A1 (en) |
EP (1) | EP0833668A4 (en) |
JP (1) | JPH11508766A (en) |
AU (1) | AU699398B2 (en) |
CA (1) | CA2224477A1 (en) |
WO (1) | WO1997000698A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000028009A1 (en) * | 1998-11-11 | 2000-05-18 | Melbourne Health | Biological compositions, components thereof and uses therefor |
KR100473240B1 (en) * | 1997-12-10 | 2005-05-16 | 구어베트 소시에테 아노님 | Metal chelates of substituted polyaminocarboxylic macrocycles and their use in diagnostic imaging |
US20120251569A1 (en) * | 2009-08-07 | 2012-10-04 | Transgene Sa | Composition for treating hbv infection |
US20130011435A1 (en) * | 2009-08-07 | 2013-01-10 | Transgene Sa | Composition for treating hbv infection |
EP3865145A4 (en) * | 2018-10-12 | 2022-08-31 | Riken | Hepatitis b virus replication inhibitor and pharmaceutical composition comprising same for treating hepatitis b |
US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7015317B2 (en) * | 2002-05-02 | 2006-03-21 | Abbott Laboratories | Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859465A (en) * | 1984-04-20 | 1989-08-22 | The Regents Of The University Of California | Vaccine capable of eliciting multivalent antibodies |
-
1996
- 1996-06-20 JP JP9503930A patent/JPH11508766A/en active Pending
- 1996-06-20 AU AU62844/96A patent/AU699398B2/en not_active Ceased
- 1996-06-20 EP EP96921695A patent/EP0833668A4/en not_active Withdrawn
- 1996-06-20 WO PCT/US1996/010602 patent/WO1997000698A1/en not_active Application Discontinuation
- 1996-06-20 CA CA002224477A patent/CA2224477A1/en not_active Abandoned
-
2001
- 2001-03-20 US US09/812,862 patent/US20020035081A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
BLUM H E, ET AL.: "Naturally Occurring Missense Mutation in the Polymerase Gene Terminating Hepatitis B Virus Replication", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 65, no. 4, 1 April 1991 (1991-04-01), US, pages 1836 - 1842, XP002963167, ISSN: 0022-538X * |
MELEGARI M, BRUNO S, WANDS J R: "Properties of Hepatitis B Virus Pre-S1 Deletion Mutants", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 199, 1 January 1994 (1994-01-01), AMSTERDAM, NL, pages 292 - 300, XP002963153, ISSN: 0042-6822, DOI: 10.1006/viro.1994.1127 * |
See also references of EP0833668A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100473240B1 (en) * | 1997-12-10 | 2005-05-16 | 구어베트 소시에테 아노님 | Metal chelates of substituted polyaminocarboxylic macrocycles and their use in diagnostic imaging |
WO2000028009A1 (en) * | 1998-11-11 | 2000-05-18 | Melbourne Health | Biological compositions, components thereof and uses therefor |
US20120251569A1 (en) * | 2009-08-07 | 2012-10-04 | Transgene Sa | Composition for treating hbv infection |
US20130011435A1 (en) * | 2009-08-07 | 2013-01-10 | Transgene Sa | Composition for treating hbv infection |
US9393299B2 (en) | 2009-08-07 | 2016-07-19 | Transgene S.A. | Composition for treating HBV infection |
US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
US10857226B2 (en) | 2009-08-07 | 2020-12-08 | Transgene S.A. | Composition for treating HBV infection |
EP3865145A4 (en) * | 2018-10-12 | 2022-08-31 | Riken | Hepatitis b virus replication inhibitor and pharmaceutical composition comprising same for treating hepatitis b |
US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
US11730808B2 (en) | 2019-09-30 | 2023-08-22 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
Also Published As
Publication number | Publication date |
---|---|
US20020035081A1 (en) | 2002-03-21 |
EP0833668A4 (en) | 2001-12-12 |
EP0833668A1 (en) | 1998-04-08 |
JPH11508766A (en) | 1999-08-03 |
AU6284496A (en) | 1997-01-22 |
AU699398B2 (en) | 1998-12-03 |
CA2224477A1 (en) | 1997-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scaglioni et al. | Posttranscriptional regulation of hepatitis B virus replication by the precore protein | |
Persing et al. | The preS1 protein of hepatitis B virus is acylated at its amino terminus with myristic acid | |
Koschel et al. | Hepatitis B virus core gene mutations which block nucleocapsid envelopment | |
US5610050A (en) | Methods of preventing viral replication | |
Sureau et al. | Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus | |
US6258937B1 (en) | Hepadnavirus receptor | |
Repp et al. | Detection of a hepatitis B virus variant with a truncated X gene and enhancer II | |
Bartenschlager et al. | Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites | |
Günther et al. | Analysis of hepatitis B virus populations in an interferon-α-treated patient reveals predominant mutations in the c-gene and changing e-antigenicity | |
Wasenauer et al. | A cysteine and a hydrophobic sequence in the noncleaved portion of the pre-C leader peptide determine the biophysical properties of the secretory core protein (HBe protein) of human hepatitis B virus | |
AU699398B2 (en) | Inhibition of hepatitis B replication | |
JPH07503615A (en) | hepatitis drug | |
Zhang et al. | Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections | |
WO1998009649A1 (en) | Inhibition of viral replication | |
AU656136B2 (en) | Methods of preventing viral replication | |
Urban et al. | In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop. | |
Raney et al. | Complex regulation of transcription from the hepatitis B virus major surface antigen promoter in human hepatoma cell lines | |
Gerlich | Structure and molecular virology | |
Seifer et al. | Expression pattern of the hepatitis B virus genome in transfected mouse fibroblasts | |
AU4315689A (en) | Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders | |
Yu et al. | The GDPAL region of the pre-S1 envelope protein is important for morphogenesis of woodchuck hepatitis virus | |
CN1050044A (en) | As vaccine or be used for the treatment of the defective hepatitis virus of liver disease | |
Persing | Identification and characterization of the presurface proteins of hepatitis B virus | |
Delaney IV | Generation, characterization, and use of the HBV baculovirus-HepG2 system: A novel in vitro model system for studying hepatitis B virus | |
WO1999021882A1 (en) | Hbv binding polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2224477 Country of ref document: CA Ref country code: CA Ref document number: 2224477 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 503930 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996921695 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996921695 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996921695 Country of ref document: EP |